Targeting small arteries of hypertensive status with novel ATP-sensitive potassium channel openers

Current Vascular Pharmacology

Volumn 3, Issue 2, 2005, Pages 119-124

  Wang, Hai ^a,b   Zhang, Ying Li ^a,b   Chen, Yu Ping ^a,b  

^a BEIJING INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (China)

^b Thadweik Academy of Medicine   (China)

Author keywords

ATP sensitive potassium channel; Cardiovascular remodeling; Hypertension; Iptakalim; Selective hypotensive efficacy; Side effects; Small artery; Vasodilator

Indexed keywords

4 AMINOBUTYRIC ACID; AMINE; ANTIHYPERTENSIVE AGENT; ASPARTIC ACID; BENZOPYRAN DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIMAKALIM; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CELIKALIM; CROMAKALIM; DIAZOXIDE; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FORMAMIDE DERIVATIVE; GLUTAMIC ACID; GUANIDINE DERIVATIVE; IPTAKALIM; METHANOL DERIVATIVE; MINOXIDIL; NIFEDIPINE; NUCLEOSIDE DIPHOSPHATASE; PINACIDIL; POTASSIUM CHANNEL STIMULATING AGENT; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; SULFONYLUREA RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ARTERY CONSTRICTION; BLOOD PRESSURE; BRAIN ISCHEMIA; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; DOG; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG POTENCY; DRUG RESPONSE; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERANCE; EDEMA; ENDOCRINE DISEASE; FLUSHING; GENE TARGETING; HEART PALPITATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPNOSIS; HYPOTENSION; NONHUMAN; RENOVASCULAR HYPERTENSION; RESPIRATORY TRACT DISEASE; REVIEW; SEDATION; SPONTANEOUSLY HYPERTENSIVE RAT; STRUCTURE ANALYSIS; TACHYCARDIA; TREATMENT OUTCOME; VASODILATATION;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANTIHYPERTENSIVE AGENTS; ARTERIES; DRUG DELIVERY SYSTEMS; DRUG TOLERANCE; HUMANS; HYPERTENSION; POTASSIUM CHANNELS;

EID: 18144383488     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/1570161053586895     Document Type: Review

References (39)

1. Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. Cell 2001; 104(4): 545-556
2. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med 1992; 117(3): 234-242
3. Vandenberg JI, Lummis SC. Ion channels--a plethora of pharmaceutical targets. Trends Pharmacol Sci 2000; 21(11): 409-10.
4. Coghlan MJ, Carroll WA, Gopalakrishnan M. Recent developments in the biology and medicinal chemistry of potassium channel modulators: update from a decade of progress. J Med Chem 2001; 44(11): 1627-53.
5. + channels. Prog Biophys Mol Biol 2003; 81(2): 133-76.
6. Sturgess NC, Ashford ML, Cook, DL, Hales CN. The sulphonylurea receptor may be an ATP-sensitive potassium channel. Lancet 1985; 2(98453): 474-475.
7. Shieh CC, Coghlan M, Sullivan JP, Gopalakrishnan M. Potassium channels: molecular defects, diseases, and therapeutic opportunities. Pharmacol Rev 2000; 52(4): 557-94.
8. + channel opening: a new drug principle in cardiovascular medicine. Heart 1996; 76(2): 109-16.
9. + channels in arterial smooth muscle. Science 1989; 245(4914): 177-80.
10. + channels in pancreatic B-cells. Nature 1984; 311(5983): 271-273.
11. + channels in cardiac muscle. Nature 1983; 305(5930): 147-8.
12. Kazic T and Gojkovic-Bukarica L. Ion channels and drug development focus on potassium channels and their modulators. Med Biol 1999; 6(1): 23-30.
13. + channel openers. Pharmacol Ther 2000; 85(1): 39-53.
14. Zhang HL, Bolton TB. Two types of ATP-sensitive potassium channels in rat portal vein smooth muscle cells. Br J Pharmacol 1996; 118(1): 105-14.
15. Wang H. Cardiovascular ATP-sensitive K+ channel as a new molecular target for development of anti-hypertensive drugs. Acta Pharmacol Sin 1998; 19(5): 397-402.
16. Wang H. Pharmacological characteristics of the novel antihypertensive drug, iptakalim hydrochloride, and its molecular mechanisms. Drug Dev Res 2003; 58(1): 65-8.
17. Ashwood VA, Buckingham RE, Cassidy F, et al. Synthesis and anti-hypertensive activity of 4-(cyclic amido)-2H-1-benzopyrans. J Med Chem 1986; 29(11): 2194-201.
18. Wang H, Yang RF, Lu XQ, et al. The novel amine derivatives modulating potassium channels, preparation and the pharmaceutical application. China Patent CN1365967A.
19. Chen YP, Yin XF, Cui WY, et al. Effects of 2,3-dimethyl-2-butylamine derivatives on potassium channels in arterial smooth muscle cells from rats. Chin Pharmacol Bull 2003; 19(5): 680-5.
20. Wang H, Yang RF, Lu XQ, et al. The novel amine derivatives modulating the functions of potassium channels. International Patent PCT/CN02/00029
21. Jia GD, Cui WY, Long CL, Liu GS, Wang H. Selective vasodilating action in small artery and it pharmacological mechanisms of novel anti-hypertensive drug iptakalim hydrochloride. Chin J Clin Pharmacol Ther 2004; 9(2): 140-5.
22. + channel openers on aorta and pulmonary artery isolated from spontaneously hypertensive and Wistar-Kyoto rats. Eur J Pharmacol 1999; 365(2-3): 241-51.
23. + channels in the vertebrobasilar system of the rabbit. Circ Res 1996; 78(2): 238-43.
24. + channels in pancreatic, cardiac, and vascular smooth muscle cells. Am J Physiol 1998; 274(1 Pt 1): C25-37.
25. Wilde AA. Role of ATP-sensitive K+ channel current in ischemic arrhythmias. Cardiovasc Drugs Ther 1993; 7 (Suppl 3): 521-6.
26. Liu W, Long CL, Lu SX, Xiao WB, Wang H. Effects of iptakalim hydrochloride on the function of rat isolated working hearts. Chin Pharmacol Bull 2002; 18(3): 349-51.
27. Tucker SJ, Gribble FM, Zhao C, et al. Truncation of Kir6.2 produces ATP-sensitive K+ channels in the absence of the sulphonylurea receptor. Nature 1997; 387(6629): 179-83.
28. Long CL, Zhu QL, Wang AP, Sun HY, Wang H. Study on selective anti-hypertensive effects of iptakalim hydrochloride. Chin J Clin Pharmacol Ther 2003; 8(5): 494-8.
29. Long CL, Xiao WB, Wang H. Effects of iptakalim hydrochloride on hypertensive vascular remodeling. Chin J Hyper 2003; 11(3): 248-50.
30. Xie WP, Wang H, Li BZ, Hu G. Effects of iptakalim, a novel ATP-sensitive potassium channel opener, on hypoxia-induced pulmonary vascular remodeling in rats. Chin J Appl Physiol 2003; 19(4): 4-7.
31. Long CL, Feng HS, Wang H. Effects of iptakalim hydrochloride on hypertensive cardiac remodeling. Chin Pharmacol Bull 2003; 19(1): 48-51.
32. Wang H, Yang RF, Long CL, et al. The novel amine derivatives against ischemia-induced neural damage and their pharmaceutical application. China Patent CN1365966A.
33. Ding JH, Tang XC, Wang H, Hu G. Effects of ATP-sensitive potassium channel opener iptkamine on levels of amino acid transmitters from hippocampus of global cerebral ischemic gerbils. J Nanjing Mil Med Coll 2000; 22(4): 229-33
34. Tang XC, Rao MR, Hu G, Wang H. Alterations of amino acid levels from striatum, hippocampus, and cerebral cortex induced by global cerebral ischemia in gerbil. Acta Pharmacol Sin 2000; 1(9): 819-23.
35. Yang YL, Meng CH, Ding JH, Hu G. Iptakalim hydrochloride enhances glutamate uptake activity in synaptosomes from rat models of Parkinsons disease. Chin Pharmacol Bull 2004; 20(1): 65-8.
36. Zhang YL, Feng HS, Wang H. Effects of Iptakalim hydrochloride on apoptosis of primary cultured cortical neurons induced by hypoxia. Chin J Clin Pharmacol Ther 2004; 9(1): 20-4.
37. Zhang YL, Wang H. Effects of Iptakalim hydrochloride on glutamate-induced cytotoxicity in cultured pheochromocytoma (PC12) cells. Chin Pharmacol Bull 2003; 19(6): 640-2.
38. Yao HH, Zhang Y, Ding JH, et al. Inhibitory effects and mechanisms of iptakalim on the glutamate release from PC12 cells induced by high K+. Chin J Clin Pharmacol Ther 2003; 8(1): 1-5.
39. Chobanian AV, Bakris GL, Black HR, et al. Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42(6): 1206-52.